30th Mar 2022 12:15
(Alliance News) - GlaxoSmithKline PLC said on Wednesday it started the clinical development of its second-generation Covid-19 vaccine candidate, CV2CoV, along with German biopharmaceutical company CureVac NV.
The Brentford, England-based pharmaceutical company said the first participant in a phase one study of the candidate had been dosed.
The trial is being conducted at clinical sites in the US and is expected to enrol up to 210 adults to evaluate the safety, reactogenicity and immunogenicity of CV2CoV in the dose range of 2 to 20 micrograms.
Results from the phase one study are expected in the second half of 2022.
A preclinical study of CV2CoV, published in November, demonstrated rapid induction of higher antibody titers, better induction of immune memory and stronger protective efficacy of CV2CoV compared to CureVac's first-generation vaccine candidate, CVnCoV.
The CureVac-GSK infectious disease collaboration was first announced in July 2020 and focuses on the development of new products based on CureVac's mRNA technology for different targets in infectious diseases.
Shares in GSK were up 0.3% at 1,646.82 pence on Wednesday in London.
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline